Trial of Lixisenatide in Early Parkinson’s Disease

利西塞纳泰德 帕金森病 安慰剂 左旋多巴 物理疗法 临床终点 随机对照试验 置信区间 评定量表 医学 疾病 内科学 心理学 糖尿病 内分泌学 2型糖尿病 替代医学 病理 发展心理学 基础胰岛素
作者
Wassilios G. Meissner,Philippe Rémy,Caroline Giordana,David Maltête,Pascal Derkinderen,Jean‐Luc Houéto,Mathieu Anheim,Isabelle Bénatru,Thomas Boraud,Christine Brefel‐Courbon,Nicolas Carrière,Hélène Catalá,Mahmoud Charif,Olivier Colin,Jean‐Christophe Corvol,Philippe Damier,Estelle Dellapina,David Devos,Sophie Drapier,Margherita Fabbri
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:390 (13): 1176-1185 被引量:385
标识
DOI:10.1056/nejmoa2312323
摘要

BACKGROUND: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent. RESULTS: A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%. CONCLUSIONS: In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于晏的应助被兔子采纳,获得10
1秒前
彭于晏的应助被潦草采纳,获得10
1秒前
shenkekeshen的应助被KuoHu采纳,获得30
1秒前
孟长歌完成签到,获得积分10
2秒前
会飞的鱼完成签到,获得积分10
2秒前
Oneone发布了新的文献求助50
3秒前
拾桉完成签到 ,获得积分10
3秒前
7秒前
8秒前
丘比特的应助被执着的觅露采纳,获得10
8秒前
9秒前
18781913856完成签到,获得积分10
9秒前
svt177188完成签到,获得积分20
9秒前
10秒前
bkagyin的应助被不弃采纳,获得10
10秒前
丘比特的应助被ku采纳,获得10
11秒前
12秒前
傻子完成签到,获得积分10
13秒前
shine完成签到,获得积分10
14秒前
ccmm发布了新的文献求助10
14秒前
学霸业的应助被9979采纳,获得10
14秒前
潦草发布了新的文献求助10
14秒前
dd完成签到,获得积分20
14秒前
上官若男的应助被兔子采纳,获得10
15秒前
米歇尔发布了新的文献求助10
15秒前
搜集达人的应助被是小鱼采纳,获得10
16秒前
SciGPT的应助被taoshiren采纳,获得10
16秒前
科研通AI2S的应助被18781913856采纳,获得10
16秒前
充电宝的应助被田园采纳,获得10
19秒前
娇娇尚发布了新的文献求助10
19秒前
完美世界的应助被花花采纳,获得10
20秒前
21秒前
21秒前
SciGPT的应助被kalani采纳,获得10
21秒前
潦草完成签到,获得积分20
21秒前
22秒前
明亮白山完成签到 ,获得积分10
22秒前
祁安完成签到,获得积分10
23秒前
tian完成签到 ,获得积分10
24秒前
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189382
求助须知:如何正确求助?哪些是违规求助? 9576691
关于积分的说明 21849410
捐赠科研通 7787318
什么是DOI,文献DOI怎么找? 3435538
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509